Ledipasvir-sofosbuvir combo safe, effective for elderly hep C patients

 Ledipasvir-sofosbuvir combo safe, effective for elderly hep C patients

March 18, 2016

By Lorraine L Janeczko

NEW YORK (Reuters Health) - The combination of ledipasvir and sofosbuvir (LDV/SOF) is safe, effective and well tolerated in people over 65 who have genotype 1 hepatitis C, researchers have found.

"This study, which is the largest analysis ever done in the population over 65, found that the combination of the NS5A inhibitor ledipasvir with the nucleotide polymerase inhibitor sofosbuvir for hepatitis C is not only highly effective but is also safe and tolerable," Dr. Sammy Saab from the David Geffen School of Medicine at the University of California, Los Angeles, told Reuters Health.

Dr. Saab has multiple financial ties, including stock ownership, to Gilead Sciences, which makes LDV/SOF.

Continue reading..

Of Interest
International Conference on Viral Hepatitis (ICVH) 2016.

Conference News

New Hep C Treatments Cause Adverse Effects in the Elderly
Medscape Medical News

Shortened Hep C Combo Passes Real-World Test
Medscape Medical News, March 18, 2016

Rhode Island Hep C Complications Projected to Continue
Medscape Medical News, March 17, 2016

Opioid Substitutes Do Not Impede Hep C Combo Drugs
Medscape Medical News, March 16, 2016

Hep B Cure Talks, Hep C Treatment Gaps Lead Conference
Medscape Medical News, March 9, 2016